C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes.
Phase of Trial: Phase IV
Latest Information Update: 08 Feb 2016
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 08 Feb 2016 New trial record